March 30, 2011 (Toronto, Ontario) — Caregivers using a transdermal patch to administer cholinesterase inhibitor (ChEI)–based therapy in individuals with Alzheimer's disease (AD) report greater overall ...

BRIDGEWATER, N.J., Jan. 14, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced that it has received FDA approval for a generic version of Exelon ® Patch (Rivastigmine ...

According to the World Health Organization (WHO), an estimated 50 million people are living with dementia globally. This number is projected to increase to 82 million by 2030 and over 150 million by ...

Luye Pharma Group today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma México, S.A. de C.V and Exeltis Pharmaceuticals Holding, S.L (Exeltis), ...

China’s National Medical Products Administration has approved Sino Biopharmaceutical Ltd.’s rivastigmine transdermal patch to treat mild to moderate Alzheimer’s disease. Developed by Sino Biopharm, ...

Breckenridge has received the Food and Drug Administration’s green light for rivastigmine transdermal system in dosage strengths of 4.6mg/24 hours, 9.5mg/24 hours and 13.3mg/24 hours. The product is ...

Researchers aimed to compare the risk of pneumonia with the use of donepezil, oral rivastigmine, transdermal rivastigmine, galantamine, and memantine. Compared to other anti-dementia medications, ...

Workers for Toyota in Brazil voted overwhelmingly on Sunday to approve a plan for temporary layoffs following storm damage to one of the Japanese carmaker's factories in the state of Sao Paulo, ...

1. Esketamine, which will be sold by Johnson & Johnson under the brand name Spravato, is a nasal spray to treat intractable depression. It is controversial due to its potential for abuse. 2.

DUBLIN — Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine ...